scispace - formally typeset
Search or ask a question
Institution

McMaster University

EducationHamilton, Ontario, Canada
About: McMaster University is a education organization based out in Hamilton, Ontario, Canada. It is known for research contribution in the topics: Population & Health care. The organization has 41361 authors who have published 101269 publications receiving 4251422 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: Significant differences in the relation of psychosocial factors to risk of myocardial infarction in 24767 people from 52 countries were found, suggesting that approaches aimed at modifying these factors should be developed.

2,110 citations

Journal ArticleDOI
TL;DR: This activity describes the rationale for using carotid ultrasound to identify subclinical vascular disease and to evaluate cardiovascular disease risk, and explains the key components of interpreting carOTid ultrasound studies for cardiovascular Disease risk assessment.
Abstract: Continuing Medical Education Course for "Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement for the American Society of Echocardiography Carotid Intima-Media Thickness Task Force" Accreditation Statement The American Society of Echocardiography is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Echocardiography designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits ™. Physicians should only claim credit commensurate with the extent of their participation in the activity. ARDMS and CCI recognize ASE's certificates and have agreed to honor the credit hours toward their registry requirements for sonographers. The American Society of Echocardiography is committed to resolving all conflict of interest issues, and its mandate is to retain only those speakers with financial interests that can be reconciled with the goals and educational integrity of the educational program. Disclosure of faculty and commercial support sponsor relationships, if any, have been indicated. Target Audience 1. Physicians, physicians' assistants, and nurses with an interest in cardiac and vascular imaging, preventive cardiology, and cardiovascular disease risk assessment. 2. Ultrasonographers with interest in vascular imaging and cardiovascular disease risk assessment. Objectives Upon completing this activity, participants will be able to: 1. Describe the rationale for using carotid ultrasound to identify subclinical vascular disease and to evaluate cardiovascular disease risk. 2. Explain the application of carotid ultrasound to cardiovascular disease risk assessment. 3. Describe the scanning technique for identifying subclinical vascular disease using carotid ultrasound. 4. Explain the key components of interpreting carotid ultrasound studies for cardiovascular disease risk assessment. Authors Disclosures James H. Stein, MD, FASE: Research grants: Siemens Medical Solutions, Sonosite Intellectual property: listed as the inventor of Patent #US 6,730,0235 "Ultrasonic Apparatus and Method for Providing Quantitative Indication of Risk of Coronary Heart Disease." It has been assigned to the Wisconsin Alumni Research Foundation. Emile R. Mohler III, MD: Speakers bureau for Merck, BMS-Sanofi and AstraZeneca; Research grant support from BMS-Sanofi, Pfizer and GSK. Christopher M. Rembold, MD: Advisory Board for Sonosite. Estimated Time to Complete This Activity: 1 hour

2,097 citations

Journal ArticleDOI
TL;DR: This damage index for SLE records damage occurring in patients with SLE regardless of its cause and was demonstrated to have content, face, criterion, and discriminant validity.
Abstract: Objective. To develop and perform an initial validation of a damage index for systemic lupus erythematosus (SLE). Methods. A list of items considered to reflect damage in SLE was generated through a nominal group process. A consensus as to which items to be included in an index was reached, together with rules for ascertainment. Each center submitted 2 assessments, 5 years apart, on 2 patients with active and 2 with inactive disease, of whom 1 had increased damage and the other had stable disease. Analysis of variance was used to test the factors physician, time, amount of damage, and activity status. Results. Nineteen physicians completed the damage index on 42 case scenarios. The analysis revealed that the damage index could identify changes in damage seen in patients with both active and inactive disease. Patients who had active disease at both time points had a higher increase in damage. There was good agreement among the physicians on the assessment of damage in these patients. Conclusion. This damage index for SLE records damage occurring in patients with SLE regardless of its cause. The index was demonstrated to have content, face, criterion, and discriminant validity.

2,095 citations

Journal ArticleDOI
TL;DR: Stress hyperglycaemia with myocardial infarction is associated with an increased risk of in-hospital mortality in patients with and without diabetes; the risk of congestive heart failure or cardiogenic shock is also increased in patients without diabetes.

2,089 citations

Journal ArticleDOI
TL;DR: The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study.
Abstract: Background Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study. Methods We conducted an international, phase 2, pivotal study of centrally manufactured tisagenlecleucel involving adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or had disease progression after autologous hematopoietic stem-cell transplantation. The primary end point was the best overall response rate (i.e., the percentage of patients who had a complete or partial response), as judged by an independent review committee. Results A total of 93 patients received an infusion and were included in the evaluation of efficacy. The median time from infusion to data cutoff was 14 ...

2,086 citations


Authors

Showing all 41721 results

NameH-indexPapersCitations
Salim Yusuf2311439252912
Gordon H. Guyatt2311620228631
Simon D. M. White189795231645
George Efstathiou187637156228
Stuart H. Orkin186715112182
Terrie E. Moffitt182594150609
John J.V. McMurray1781389184502
Jasvinder A. Singh1762382223370
Deborah J. Cook173907148928
Andrew P. McMahon16241590650
Jack Hirsh14673486332
Holger J. Schünemann141810113169
John A. Peacock140565125416
David Price138168793535
Graeme J. Hankey137844143373
Network Information
Related Institutions (5)
University of Toronto
294.9K papers, 13.5M citations

98% related

University of Pittsburgh
201K papers, 9.6M citations

94% related

University of Minnesota
257.9K papers, 11.9M citations

93% related

University of California, San Diego
204.5K papers, 12.3M citations

93% related

Northwestern University
188.8K papers, 9.4M citations

93% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023168
2022521
20216,351
20205,747
20195,093
20184,604